304.96MMarket Cap
LossP/E TTM
Organogenesis Holdings Inc
Key Figures
2.480Open
2.480High
1.06MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.82%Turnover Ratio
2.450Prev. Close
2.295Low
1.55MTurnover
LossP/E Static
1.25P/B
0.00%Div Yield TTM
0.55%ROA
7.07752wk High
1.94Volume Ratio
-937.00KNet Profit
128.67MShares
-0.1105EPS TTM
1.32Beta
-5.97%ROE
2.04052wk Low
7.55%Amplitude
30.77%Gross Margin
304.96MMarket Cap
-0.31Reward/Risk
3.86%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Organogenesis Holdings Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 114 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 3.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Organogenesis Holdings Inc's Score
Support & Resistance

Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Organogenesis Holdings Inc Highlights
StrengthsRisks
Organogenesis Holdings Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Organogenesis Holdings Inc
ORGO
2
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
Indicators
Financial Indicators
EPS

Relevant data have not been disclosed by the company yet.
Total revenue

Relevant data have not been disclosed by the company yet.
Organogenesis Holdings Inc Info
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Ticker SymbolORGO
CompanyOrganogenesis Holdings Inc
CEOGillheeney (Gary S)
Websitehttps://investors.organogenesis.com
Shareholders
FAQs
What is the current price of Organogenesis Holdings Inc (ORGO)?
The current price of Organogenesis Holdings Inc (ORGO) is 2.37.
What is the symbol of Organogenesis Holdings Inc?
The ticker symbol of Organogenesis Holdings Inc is ORGO.
What is the 52-week high of Organogenesis Holdings Inc?
The 52-week high of Organogenesis Holdings Inc is 7.08.
What is the 52-week low of Organogenesis Holdings Inc?
The 52-week low of Organogenesis Holdings Inc is 2.04.
What is the market capitalization of Organogenesis Holdings Inc?
The market capitalization of Organogenesis Holdings Inc is 304.96M.
Is Organogenesis Holdings Inc (ORGO) currently rated as Buy, Hold, or Sell?
According to analysts, Organogenesis Holdings Inc (ORGO) has an overall rating of signal_hold, with a price target of 3.00.
What is the Earnings Per Share (EPS TTM) of Organogenesis Holdings Inc (ORGO)?
The Earnings Per Share (EPS TTM) of Organogenesis Holdings Inc (ORGO) is 0.16.